Bio-link Australia Pty. Ltd.

Client Endorsements

Bio-Link’s goal is to provide to its clients professional business development and advisory services that are value-adding and insightful, executed effectively, on time and with a transparent cost. A number of Bio-Link’s valued clients have provided endorsements for current and recent work that we have performed on their behalf.

 

Antisense Logo(2)

“Bio-Link assisted us by preparing an excellent opportunity summary for presentation to potential partners and by identifying target companies with a rational fit for specific disease applications of one of our drug candidates. Bio-Link then progressed substantial discussions with several of those companies, providing valuable industry feedback and commercial insights that we incorporated into our strategic development plans for the program. We were pleased with the way Bio-Link interacted with our team, working independently as needed, yet keeping us well informed of progress and deliverables. Bio-Link is a sensible option for expanding our business development resources as needed, and we would anticipate accessing their services for future projects that may arise.”

Mark Diamond, CEO and George Tachas, Director, Drug Discovery & Patents

Antisense Therapeutics Ltd.

 


 

QRx

To Whom It May Concern:

As CEO of QRxPharma, it gives me great pleasure to strongly recommend Bio-Link as an outstanding facilitator of business development opportunities for life sciences companies.

Since 2008, Bio-Link Australia has provided professional business development and project management services to multiple programs in the QRxPharma pipeline. These programs include our preclinical peptide drug candidates under development for surgical bleeding and haemostasis applications, our TorsinA small molecule drug discovery program for neurological disorders based at the University of Alabama (USA), and pursuit of potential veterinary applications of the company’s pain management dual opioid technology.

As part of their efforts, Bio-Link has facilitated strategic commercial positioning of our programs for partnering by forging strong working relationships with our scientists and management located in Australia, Thailand and the USA.  They  created effective non-confidential and confidential selling documents summarising our technologies that they used to engage the interest of potential commercial partners throughout the global biopharma industry.

I am delighted to recommend Bio-Link as a valuable partner in the pursuit and execution of partnering and license deals for life sciences companies developing human and veterinary therapeutics programs.

Sincerely,

John W. Holaday, Ph.D.

Managing Director and CEO

QRxPharma

 


 

bionomics-spot

“Bionomics engaged Bio-Link Australia in 2011/2012 to provide business development and consulting services for two of our drug discovery programs, namely (i) our preclinical Alpha 7 Program for the potential treatment of Alzheimer’s disease, schizophrenia and Parkinson’s disease and (ii) our clinical stage BNC 105 Program for solid tumours. Bio-Link quickly understood the science and commercial goals underpinning these Programs and worked as part of the team with Bionomics senior management to strategically position the technologies for partnering discussions. In the case of the Alpha 7 Program, Bio-Link undertook a comprehensive outreach to the global biopharma industry, facilitating dialogue with potential commercial partners and gathering valuable insights to support our technology development and partnering strategies for the Program. I highly recommend Bio-Link to other biotechnology companies looking to source professional, insightful and cost effective business development capabilities for their drug development pipelines.”

Deborah Rathjen, Ph.D.

Chief Executive Officer & Managing Director

Bionomics Ltd.

 


 

Florey-Institute_RGB_web - 245x79

“As lead institution in a collaboration with St Vincent’s Institute of Medical Research, and more recently Monash University, The Florey Institute engaged Bio-Link Australia in 2009 to facilitate partnering of our IRAP drug discovery program for Alzheimer’s disease. Bio-Link under-took an extensive outreach campaign to the global industry, leading to extensive dialogue and feedback on the IRAP Program from senior scientific and business development executives from biotech and pharma companies. Bio-Link’s work ultimately led to negotiation and execution of the deal with Les Laboratoires Servier that was announced in September 2012. The deal involves a multi-disciplinary and multi-party research collaboration, with significant sponsored and leveraged funding. Bio-Link was instrumental in facilitating and closing this deal. During its engagement, Bio-Link successfully managed complex inter-personal and inter-institutional relationships within our own collaboration and assisted to strategically position the Program for industry engagement and interest. Bio-Link made a significant contribution to the  scientific strategy and worked productively with the scientists and institutions to source development funding for the program from NHMRC and Commercialisation Australia. Over the years of their engagement by The Florey, Bio-Link provided frequent reporting and transparent service fees, working as part of the team with shared risk to execute the best deal possible. I highly recommend Bio-Link to other institutions and biotech companies as a professional business development partner able to manage complex drug discovery programs and execute strategic and important drug discovery alliances with the biopharma industry.”

Henry De Aizpurua Ph.D.

Head, Business Development

The Florey Institute of Neuroscience and Mental Health

 


 

ACRF_logo_horizontal_CMYK

The Australian Cancer Research Foundation (ACRF) engaged Bio-Link to undertake a strategic consultancy and to identify opportunities for consideration by the ACRF Board. Bio-Link’s report was based on interviews with leading cancer researchers, including scientists in the USA, and a strategic analysis of global trends in cancer research. They delivered on-time and on-budget and their report was well-received by the Board. We would not hesitate to recommend Bio-Link to organisations that are seeking an independent consultancy with valuable insights, networks and experience in medical research.

David Brettell

CEO

Australian Cancer Research Foundation